(RTTNews) – Cidara Therapeutics, Inc. (CDTX) has introduced the publication of preclinical information on CD388, its investigational drug-Fc conjugate (DFC) for influenza, in Nature Microbiology. The examine highlights CD388’s potential as a broad-spectrum preventative for influenza A and B, notably for high-risk populations.
Not like conventional vaccines, CD388 is designed to supply common, long-lasting safety in opposition to each seasonal and pandemic flu strains. The examine demonstrated its effectiveness throughout all examined influenza A and B strains, together with H5N1 and drug-resistant variants. CD388 additionally confirmed a low potential for resistance growth and maintained efficacy in each immune-competent and immune-compromised fashions.
Presently being evaluated within the Part 2b NAVIGATE trial with ~5,000 members, CD388 is formulated as a long-acting small molecule inhibitor that doesn’t depend on an immune response. This makes it a promising choice for people with weakened immunity.
CEO Jeffrey Stein emphasised that whereas vaccines stay important, they don’t present ample safety for all populations, highlighting the necessity for sturdy antiviral options like CD388. Chief Scientific Officer Les Tari famous that the DFC platform enhances the efficacy and longevity of focused therapies, positioning CD388 as a possible game-changer in influenza prevention.
CDTX is at the moment buying and selling at $22.14 or 0.41% greater on the Nasdaq Capital Market.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.
